MiMedx Group MDXG Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81%-1.5pp | 82.6%+0.6pp | 82%+0.5pp | 81.5%-0.5pp | 81.9%-0.8pp | |
| Operating margin | 10.2%-5.1pp | 15.3%+1.6pp | 13.7%+1.9pp | 11.8%-3.5pp | 15.3%-1.6pp | |
| Net margin | 7.9%-3.7pp | 11.6%+1.2pp | 10.4%+1.5pp | 8.8%-2.6pp | 11.4%-0.8pp | |
| EBITDA margin | 13.1%-5.7pp | 18.8%+1.9pp | 16.9%+2.3pp | 14.7%-3.0pp | 17.6%-1.0pp | |
| Free cash flow margin | 17.8%+0.4pp | 17.4%+0.4pp | 17%+1.3pp | 15.7%-2.6pp | 18.3%-0.2pp | |
| Returns | ||||||
| Return on equity | 13.8%-7.8pp | 21.6%+2.2pp | 19.4%+2.7pp | 16.7%— | —— | |
| Return on assets | 10.6%-5.4pp | 16%+1.5pp | 14.5%+2.2pp | 12.3%-4.0pp | 16.3%-0.5pp | |
| Return on invested capital | 26.6%-14.7pp | 41.4%+6.5pp | 34.9%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 1.3×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | |
| Inventory turnover | 2.9×0.0× | 3×+0.2× | 2.8×+0.1× | 2.7×+0.1× | 2.6×-0.1× | |
| Liquidity | ||||||
| Current ratio | 5.4×+1.1× | 4.3×-0.1× | 4.4×0.0× | 4.4×-0.3× | 4.7×+0.5× | |
| Quick ratio | 4.8×+0.9× | 3.9×0.0× | 3.9×0.0× | 3.9×-0.2× | 4.1×+0.4× | |
| Cash ratio | 3.6×+1.0× | 2.6×+0.1× | 2.5×+0.1× | 2.4×-0.1× | 2.5×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -2.8×-1.0× | -1.8×0.0× | -1.9×0.0× | -1.9×-0.5× | -1.4×-0.2× | |
| Per Share | ||||||
| Book value per share | $1.64-4.5% | $1.71+7.4% | $1.60+10.0% | $1.45+7.1% | $1.35+4.6% | |
| Valuation | ||||||
| Market capitalization | $567.48M-33.9% | $1B-2.9% | $1.03B+17.3% | $880.3M-21.4% | $1.12B-20.8% | |
| Enterprise value | $425.3M-44.8% | $859.06M-5.5% | $908.89M+16.5% | $779.9M-24.4% | $1.03B-22.6% | |
| Price / earnings | 18.5×-2.9× | 20.6×-4.7× | 25.3×-2.1× | 27.4×-0.5× | 27.9×-5.5× | |
| Price / sales | 1.5×-1.0× | 2.4×-0.2× | 2.6×+0.2× | 2.4×-0.8× | 3.2×-0.9× | |
| Price / book | 2.3×-1.9× | 3.9×-0.4× | 4.3×+0.3× | 4.1×-1.5× | 5.5×-1.8× | |
| EV / EBITDA | 8.3×-4.1× | 10.9×-2.8× | 13.7×-1.0× | 14.6×-2.0× | 16.6×-4.0× | |
| EV / sales | 1.1×-1.1× | 2.1×-0.3× | 2.3×+0.2× | 2.1×-0.8× | 2.9×-0.9× | |
| Free cash flow yield | 12.2%+4.7pp | 7.3%+0.8pp | 6.5%0.0pp | 6.5%+0.7pp | 5.8%+1.2pp | |
| Earnings yield | 5.4%+0.7pp | 4.8%+0.9pp | 4%+0.3pp | 3.7%+0.1pp | 3.6%+0.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are MiMedx Group's profit margins?
- MiMedx Group (MDXG) runs a 81.0% gross margin and a 10.2% operating margin, with a 7.9% net margin.
- Where do MiMedx Group's ratios come from?
- Every ratio is computed from MiMedx Group's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
